non-small cell lung cancer
Foundation Medicine Companion Dx Test Gets FDA OK for Use with Merck's Tepmetko in Lung Cancer
The blood-based comprehensive genomic profiling test uses next-generation sequencing to analyze 324 genes.
Following a lung cancer study, the firm plans to initiate similar studies in other cancers and to launch a new tumor profiling assay later this year.
Foundation Medicine, Merus to Develop CDx for Cancer Drug to Treat Patients With NRG1 Fusions
The companies will use Foundation's RNA sequencing platform to develop a companion diagnostic for Merus' bispecific antibody zenocutuzumab.
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
Roche PD-L1 Assay Nabs Expanded CE Mark as CDx for Libtayo, Chemotherapy Combo
The Ventana assay previously received CE marking for identifying patients with lung cancer who may benefit from treatment with Libtayo.
Apr 12, 2024